Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in
slowing tumor activity in patients with metastatic pancreatic cancer who have previously
received 1st line treatment with a gemcitabine regimen. The study is also looking at the
safety of S-1.